Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Augmenix Inc.

Division of Boston Scientific Corp.
https://www.spaceoar.com

Latest From Augmenix Inc.

Market Intel: Let's Talk About It — The Rising Tide Of 'Femtech' Companies

Femtech, which describes digital technologies that aim to improve women's health, is expected to reach $50bn in market size by 2025, according to Frost & Sullivan. Reproductive health and menstrual health trackers are two of the fastest-growing sectors in femtech. We've highlighted some of the biggest players in both segments, their innovative business models, plans and also looked at barriers such as privacy issues, accuracy of mobile applications and funding challenges.

Market Intelligence Commercial

Boston Scientific Invests In Urology With $600M Augmenix Acquisition

Augmenix is the privately-held developer of SpaceOAR, an injected hydrogel spacer that is indicated for reducing collateral damage from radiation treatment for prostate cancer. It addresses a market worth about $750m, with total sales expected to reach $90m in 2019.

M & A Commercial

Augmenix Looks To Apply Hydrogel Technology Beyond Prostate Cancer

The company's SpaceOAR injected hydrogel spacer continues to prove effective at reducing the collateral damage from radiation treatment for prostate cancer. Now the Boston company hopes to apply the same bioabsorbable hydrogel technology to improve outcomes with radiation therapy for other cancers, including pancreatic and gynecological cancer.

Clinical Trials Innovation

OUS Approvals Analysis: IVDs Lead A Slow Month

Only 10 approvals from outside the US were recorded in May in Medtech Insight's approvals tracker. Half of those were for in vitro diagnostics, including three for companion diagnostic for cancer drugs.

Approvals Innovation
See All

Company Information

  • Industry
  • Biotechnology
  • Medical Devices
    • Biomaterials
    • Implantable Devices
  • Therapeutic Areas
  • Cancer
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Boston Scientific Corp.
  • Senior Management
  • John Pedersen, Pres. & CEO
    Ken Knudson, VP, Global Sales & Mktg.
    Pat Campbell, PhD, CTO
    David Inman, VP, Fin.
  • Contact Info
  • Augmenix Inc.
    Phone: (781) 895-3235
    201 Burlington Rd.
    Bedford, MA 01730
    USA
UsernamePublicRestriction

Register